Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{179308,
        author = {Dr. Mayuri Gurav and Mr.Ganesh More},
        title = {Molecular and Behavioral Assessment of Melia azedarach extract in Parkinsonian rat models with novel nano-ethosomal gel formulation},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {11},
        number = {12},
        pages = {6088-6100},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=179308},
        abstract = {Objectives: Melia azedarach Linn., a member of the Meliaceae family, is traditionally valued in Ayurveda for its medicinal qualities, characterized by its Tikta and Kashaya tastes, Sheeta (cooling) potency, and Ruksha (dry) nature. It is known for a wide range of pharmacological actions, making it beneficial in various health disorders. This study was designed to investigate the anti-Parkinsonian potential of an ethanolic leaf extract of Melia azedarach in animal models of Parkinson’s disease induced by haloperidol and 6-hydroxydopamine (6-OHDA), along with the formulation of a nano-based delivery system for targeted treatment. Methods: Adult male Wistar rats (180–220 g) were randomly assigned to six groups (n=6), each subjected to a specific intervention. Haloperidol was used to induce catalepsy, while 6-OHDA was administered to mimic Parkinsonian symptoms. The experimental groups included a normal control (distilled water), a vehicle control (6-OHDA + saline), a disease control (6-OHDA alone), a standard group receiving Levodopa, and two test groups receiving Melia azedarach extract at 100 mg/kg and 200 mg/kg subcutaneously for 48 days. Behavioral assessments focused on catalepsy, muscle stiffness, and locomotor activity. Phytochemical profiling was carried out using UV and IR spectroscopy, while molecular docking was performed using AutoDock. SwissADME was employed to evaluate pharmacokinetic properties. A nano ethosomal gel was developed and characterized based on particle size, zeta potential, pH, drug content, texture, viscosity, and spreadability. Results: Computational studies identified flavonoids such as Nobiletin, Quercetin, and Kaempferol as key contributors the observed neuroprotective effects. These compounds showed higher binding affinity in molecular docking analyses than Levodopa. The 200 mg/kg dose of Melia azedarach significantly reduced haloperidol-induced catalepsy and improved motor function in the 6-OHDA model. Conclusion: Melia azedarach leaf extract demonstrated promising anti-Parkinsonian effects by improving motor deficits in experimental models. The nano ethosomal gel formulation enhances its potential for targeted brain delivery, suggesting therapeutic promise in Parkinson’s disease management.},
        keywords = {Anti-Parkinson effects, Melia azedarach, Molecular interaction studies, Nano-based ethosomal formulation, Parkinson's disease experimental models.},
        month = {May},
        }